Breaking Finance News

Zacks Investment Research upgraded Mylan N.V. (NASDAQ:MYL) to Hold in a report released today.

Yesterday Mylan N.V. (NASDAQ:MYL) traded 0.43% higher at $39.18. The company’s 50-day moving average is $31.43 and its 200-day moving average is $36.46. The last closing price is up -10.78% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time period. 4,166,479 shares of the stock traded hands, down from an average trading volume of 6,461,160

Zacks Investment Research has upgraded Mylan N.V. (NASDAQ:MYL) to Hold in a report released on 5/25/2017.

See Chart Below

Mylan N.V. (NASDAQ:MYL)

Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87 with a P/E ratio of 26.30 The company’s market cap is currently $0.

General Information About Mylan N.V. (NASDAQ:MYL)

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; antiretroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures; and Dymista, which is used for the treatment of seasonal allergic rhinitis. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hatfield, the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *